Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.

Parmakhtiar B, Burger RA, Kim JH, Fruehauf JP.

Mol Cancer Res. 2019 Aug;17(8):1675-1686. doi: 10.1158/1541-7786.MCR-18-1109. Epub 2019 May 14.

PMID:
31088908
2.

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.

Fruehauf JP, El-Masry M, Osann K, Parmakhtiar B, Yamamoto M, Jakowatz JG.

Cancer Chemother Pharmacol. 2018 Aug;82(2):353-360. doi: 10.1007/s00280-018-3624-6. Epub 2018 Jun 25.

3.

Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels.

Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, Lilly M, Zi X.

Neoplasia. 2011 Feb;13(2):108-19.

4.

Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture.

Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf JP.

Angiogenesis. 2010 Dec;13(4):305-15. doi: 10.1007/s10456-010-9187-8. Epub 2010 Oct 7.

5.

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP.

Gynecol Oncol. 2010 Dec;119(3):484-90. doi: 10.1016/j.ygyno.2010.08.016. Epub 2010 Sep 25.

Supplemental Content

Loading ...
Support Center